GLP-1 Drugs and Suicide Risk: Meta-Analysis Finds No Significant Association
Meta-analysis of GLP-1 agonists and suicidal ideation finds no significant association, providing further reassurance on the psychiatric safety of these widely used drugs.
Quick Facts
What This Study Found
Meta-analysis of GLP-1 agonists and suicidal ideation finds no significant association, providing further reassurance on the psychiatric safety of these widely used drugs.
Key Numbers
Searched 6 databases from first published article through October 2024. Found no statistically significant increase in suicidal ideation or suicide completion.
How They Did This
Clinical or preclinical study with methodology detailed in the full publication.
Why This Research Matters
This finding has implications for the millions of patients using or considering peptide-based therapies.
The Bigger Picture
This study adds to the rapidly expanding evidence base for peptide-based therapeutics across multiple medical specialties.
What This Study Doesn't Tell Us
Study-specific limitations are discussed in the full publication. As with all research, findings should be interpreted in the context of study design and population.
Questions This Raises
- ?What are the long-term implications of these findings?
- ?How do these results compare to other studies in this area?
- ?What further research is needed to confirm and extend these findings?
Trust & Context
- Key Stat:
- Key finding Meta-analysis of GLP-1 agonists and suicidal ideation finds no significant association, providing fu
- Evidence Grade:
- Evidence grade assessment based on study design and methodology detailed in the full publication.
- Study Age:
- Published in 2025. Reflects current state of peptide therapeutic research.
- Original Title:
- Assessing the shadows: A meta-analysis of GLP-1 agonists and suicidal ideation.
- Published In:
- Medicine, 104(49), e46173 (2025)
- Authors:
- Alansari, Amal Omar, Alharbi, Ahlam Saleem, Alshehri, Khaled Mohammad, Alhabib, Ali Tareq, Alsalmi, Bodour Saleh, Almosfer, Waleed Abdulaziz, AlAjlan, Fadiyah Abdullah, Alharbi, Abeer Abdullah, Alzahrani, Basmah Saleh, Alamer, Bader, Alatawi, Amirah M
- Database ID:
- RPEP-09837
Evidence Hierarchy
Combines results from multiple studies to find an overall pattern.
What do these levels mean? →Frequently Asked Questions
What does this study mean for patients?
Meta-analysis of GLP-1 agonists and suicidal ideation finds no significant association, providing further reassurance on the psychiatric safety of these widely used drugs.
How reliable are these findings?
The evidence level depends on study design. Clinical trials provide stronger evidence than case reports. Consult the full publication and discuss with your healthcare provider.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09837APA
Alansari, Amal Omar; Alharbi, Ahlam Saleem; Alshehri, Khaled Mohammad; Alhabib, Ali Tareq; Alsalmi, Bodour Saleh; Almosfer, Waleed Abdulaziz; AlAjlan, Fadiyah Abdullah; Alharbi, Abeer Abdullah; Alzahrani, Basmah Saleh; Alamer, Bader; Alatawi, Amirah M. (2025). Assessing the shadows: A meta-analysis of GLP-1 agonists and suicidal ideation.. Medicine, 104(49), e46173. https://doi.org/10.1097/MD.0000000000046173
MLA
Alansari, Amal Omar, et al. "Assessing the shadows: A meta-analysis of GLP-1 agonists and suicidal ideation.." Medicine, 2025. https://doi.org/10.1097/MD.0000000000046173
RethinkPeptides
RethinkPeptides Research Database. "Assessing the shadows: A meta-analysis of GLP-1 agonists and..." RPEP-09837. Retrieved from https://rethinkpeptides.com/research/alansari-2025-assessing-the-shadows-a
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.